https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

EHA 2025: GOLCA Plus Rituximab Shows Promise in R/R DLBCL

EHA 2025: GOLCA Plus Rituximab Shows Promise in R/R DLBCL

Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral CELMoD agent golcadomide (GOLCA) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

administrator

Related Articles